Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Highlights

An exploratory mission to Japan and South Korea for Genopole


#international #Asia #Japan #South Korea #biotech
Genopole en mission exploratoire au Japon et en Corée du sud - octobre 2023
Genopole en mission exploratoire au Japon et en Corée du sud - octobre 2023

Setting its sights on Southeast Asia, Genopole sent a team to Japan and South Korea on 7–18 October to present itself and several of its accompanied businesses to major pharmaceutical corporations, investors and Asian bioclusters curious about biotechnological innovations and open to international partnerships.

Here, Laurence Lacroix-Orio, head of the Growth Hub of Genopole’s Business Development and Prospection Department, explains the objectives of the mission and the perspectives for partnerships it obtained.

Why all this interest for Southeast Asia?

Laurence Lacroix-Orio : “Southeast Asia is a promising and dynamic market as concerns healthcare.

The Japanese benefit from the longest life expectancy in the world!
That’s an excellent accomplishment for the country, but it does imply an aging population and the health issues that go with it, notably increasing rates for cancers, neurodegenerative diseases and cardiovascular disorders, among others. That explains Japan’s significant investments to support regenerative medicine and biomedical innovation.
South Korea is also very receptive to open innovation and international partnerships.

So, this exploratory mission’s objective was to find partnership opportunities with not only major corporations and investment funds, but also local bioclusters whose focuses pair well with those of Genopole”.

Do pharmaceutical corporations also seek out partnerships?

Laurence Lacroix-Orio: “There are many pharmaceutical companies looking for licensing agreements to strengthen their drug portfolios in, for example, oncology, cardiometabolic disorders or rare diseases.

Groups such as Daïchi Sankyo in Japan and Celltrion in South Korea are looking to extend their activities to Europe. Why not at Genopole?

Form left to right: Hélène Virasith, Laurence Lacroix-Orio and Paul Caroen
From left to right: Hélène Virasith, Program Manager – Bioeconomy Advisor, Laurence Lacroix-Orio, Business Development Director and Paul Caroen, Program Manager – Health Advisor

Thanks to our mission, they now know about Genopole’s real estate advantages and building potential for biomanufacturing plants, as well as its other benefits.
We’ve launched discussions and created a climate of trust. That’s the interest of on-site visits. We were easily able to create contacts with numerous Japanese biotech actors at BioJapan, Asia’s largest biotech conference, which draws 15,000 pharmaceutics professionals every year from across the globe. This was also the case at the Global Life Science event in Tokyo, at the Pharma Partnering Conference in Osaka and at a range of clusters in Japan and South Korea.

Be they in Kawasaki or Kobe in Japan, or Innopolis, Magok or Incheon in Korea, all the locations we visited shared our vision: exchange good practices and formalize partnerships to ease the arrival of our biotechs at their sites and inversely welcome theirs to Genopole”.

Is Genopole already known in Southeast Asia?

Laurence Lacroix-Orio: “Yes. Previous contacts over the years have already established Genopole as a French site at the cutting edge of biotech innovation among Japanese and Korean academic researchers and corporations.

For example, only a month after having won the 2012 Nobel Prize for his work on induced pluripotent stem cells, Shinya Yamanaka visited Genopole and met with I-Stem Director Marc Peschanski, a French expert in stem cell research (AFM-Téléthon, Inserm, University of Évry).

Also, the Japanese company Santen and the Korean company SK pharmteco have acquired and financed businesses at Genopole. Inversely, Genopole companies like Synsight, or Texcell,—a biosecurity service provider—are spreading their wings in Japan, in Korea and in Asia generally.

We share subjects of interest and opportunities are available to us. In the wake of our exploratory mission, the Creative Economy Innovation Center, which is an innovative start-up hub in Seoul, will be visiting Genopole in the next few weeks and other connections and partnerships will follow.

Genopole: already renowned in Japan and Korea



  • Yposkesi, one of Europe’s leading contract development manufacturing organizations (CDMO) for viral vectors and gene & cell therapies, was acquired in 2021 by the Korean company SK pharmteco.
    This latter’s financing enabled a doubling of biomanufacturing surfaces at Genopole, inaugurated in 2023.

  • The Genopole company Novagali was acquired in 2011 by the Japanese ophthalmology leader Santen, which maintained research activities at Genopole (through to 2022).

Highlighted Genopole companies

The exploratory mission to Southeast Asia had the objective of presenting not only Genopole, France’s reference ecosystem for biotech, but also, and upon their request, several Genopole-accompanied biotechs to major local pharmas and investors:

  • ByoRNA, is a specialist in low-cost mRNA biomanufacturing technologie
  • Synsight is developing an artificial intelligence technology to accelerate drug discovery.
  • Enterome whose laboratories are at Genopole, develops new cancer treatments built upon intestinal microbiome–immune system interactions.
  • Quantoom Biosciences France is forwarding an innovative, considerably less-costly DNA production technology to increase the availability of vaccines and nucleic-acid-based therapies across the globe.
  • Cell Environnement, an R&D service provider specialized in the automated detection of damaged DNA, proposes telomere and centromere staining kits to enable the detection of chromosomal abnormalities.
  • Hybrigenics provides clients with research services aimed at the discovery of novel protein interactions, the identification of protein targets for drug candidates, and the selection of original VHH antibodies to target all types of antigens.
  • Fabmid develops an easy-to-produce DNA vector that shows high cell-transfection efficiency, low toxicity, high selectivity and high stability with the aim of reducing costs and improving the efficacy of gene & cell therapies.
  • Kyron.bio is a biologics engineering company looking to improve drug safety and effectiveness via protein glycosylation modifications.
  • STH Biotech is developing innovative, plant-based biotech processes to standardize the production of high-added-value cannabis compounds for the health industry.
  • EndoGene.Bio is elaborating a simple, reliable and specific endometriosis diagnostic test based on epigenetic biomarkers in menstrual blood.
  • ABCell-Bio, an expert in isolating specific cell types from umbilical cord blood, proposes ready-to-use cells and research laboratory services.
Entrepreneurship & Business Development Department – A team at your side

Laurence Lacroix-Orio

Business Development Director
laurence.lacroix@genopole.fr

Paul Caroen

Program Manager – Health Advisor
paul.caroen@genopole.fr

Stéphane Soum

Program Manager – Industry Advisor
stephane.soum@genopole.fr

Hélène Virasith

Program Manager – Bioeconomy Advisor
helen.virasith@genopole.fr

Guillaume Suinot

Conseiller implantation des entreprises
guillaume.suinot@semgenopole.fr

Article posted on 20 November 2023

Share
Highlights

The latest news


Journée Croda - table ronde intitulée « Essais cliniques phases 1 et 2 : comment surmonter les obstacles réglementaires et financiers ? » Nov. 2024

Genopole and Croda Pharma ally for the Biopharma Innovation Summit

Genopole partnered with Croda Pharma to organize the Biopharma Innovation Summit, a day-long scientific event dedicated to biopharmaceutical innovation.

Discover
Ibisc - Genopole's Laboratory

Optimizing the vital debriefing step in virtual reality training

The IBISC laboratory has developed an immersive debriefing module for virtual reality training and demonstrated its ability to optimize the vital debriefing step in that setting.

Discover
Genopole Partnering Week 2024 - un format hybride au service des biotechs

Partnering Week 2024: a hybrid edition for biotech innovation

Discover the highlights of Genopole Partnering Week 2024 (#GPW2024): a hybrid event bringing together start-ups, investors, and industry leaders to accelerate biotech innovation in health and the environment.

Discover
L'équipe de la Biofonderie de Paris dont Genopole est membre au GBA 2024 en Corée

Genopole’s actions for synthetic biology and the bioeconomy

Genopole strengthens its key roles in synthetic biology, biomanufacturing and the bioeconomy, as demonstrates its notable actions carried out this fall on several national and international scenes.

Discover
Mission Bio Japan 2024 : Abolis Biotechnologies et Ispiron, accompagnées par Laurence Lacroix-Orio, directrice du Pôle Croissance et Prospection de Genopole, Paul Caroën, Program Manager et Alexis Biton, coordinateur des affaires internationales

Genopole’s mission to Japan – a country looking to lead in bioindustry

Genopole's mission to Japan was a great opportunity to extend its international network of investors and corporations in Eastern Asia. It is opening itself to partnerships with foreign start-ups to strengthen the commercial deployment of innovative breakthroughs for regenerative medicine, gene editing and artificial intelligence.

Discover
Les projets immobilier du biocluster Genopole - Evry

Real estate at Genopole: supporting growth through a strategic offer for workspace

With more than 41,000 m² of office and lab premises & more than seven hectares of available land tracts, the real estate offer of the Genopole biocluster is actively laying the groundwork for future developments with projects such as GenoLife and Cube.

Discover
Généthon - Vers une nouvelle génération de vecteurs viraux AAV pour la thérapie généique

The road toward a new generation of gene therapy vectors

Using an AI approach, Genethon has conceived a next-generation vector improving the specificity and safety of gene therapies for muscular dystrophies.

Discover

Protopia: Genopole steps into a new era of prototyping

Protopia, a new, advanced prototyping platform aimed at transforming R&D in biotech sectors, will be a resounding next-step in support for innovative biotech start-ups and businesses. It aims to accelerate project upscaling and preindustrialization while also empowering interdisciplinary partnerships.

Discover
Equipe du laboratoire LBEPS

LBEPS : Athletic performance is also forged in the laboratory

Research performed at LBEPS has resulted in three publications illustrating how a scientific approach to exercise can optimize athletic performance and health.

Discover
Laboratoire de R&D - Abolis - campus Genopole

Abolis raises €35 million from an international consortium

Abolis has reached another milestone in its upscaling objectives. Convinced by the pertinence and robustness of its technology, an international consortium of industrials and funders will provide €35 million to the company.

Discover
Hélène Virasith, Program manager à Genopole, a accompagné trois startups génopolitaines Nutropy, AuraLIP et Onima au salon Futur Food Tech de Chicago - Juin 2024

Genopole at the Future FoodTech 2024 – Chicago

Genopole was in Chicago on June 17 and 18 for the Future Food Tech conference. Genopole® accompanied three of the biocluster's companies developing more sustainable food: Nutropy, AuraLIP and Onima. This was an opportunity for them to get noticed by major US groups and investors, and to gain an insight into North American market trends.

Discover
La délégation Genopole à BIO USA 2024

Genopole at BIO International 2024

The Genopole team at the BIO International Convention in San Diego pursued three main objectives: promote Genopole accompaniment to attract new talent, highlight biocluster companies and gather information on market and regulatory tendencies.

Discover
ACS Publication - Cover May 2024 - qui contient la publication du Lambe sur les nanopores

Lambe: A new milestone on the path to nanopore-based precision diagnostics

June 2024- Lambe has demonstrated the ability of an aerolysin nanopore to discriminate enantiomeric forms of peptide biomarkers useful for medical diagnostics.

Discover
Visite de la délégation

Genopole and the Netherlands: together to accelerate the development of alternative proteins

Genopole welcomed a Dutch delegation of close to 20 company representatives and alternative proteins researchers. The objective of the visit was to explore possibilities for research and business partnerships aimed at the development of new foods capable of meeting the future's nutritional, environmental, health, business and gustatory demands.

Discover
Adnam Imeri et Jennifer Allouche, lauréats du programme financier ATIGE, créent leur équipe de recherche à Genopole respectivement en génomique et en biothérapies.

Two new research teams working on important subjects in genomics and innovative biotherapies

With its two new Atige laureates, Adnam Imeri and Jennifer Allouche, lauréats du programme financier ATIGE, create their research teams working on important subjects in genomics and innovative biotherapies.

Discover
le programme national d’envergure PEPR Biothérapies et Bioproduction,  co-piloté par Cécile Martinat, est piloté par le CEA et l'Inserm

Four biocluster labs involved in the PEPR national program

Launched in late 2023 as part of the France 2030 plan, the PEPR "Biotherapies and Biomanufacturing" program seeks to place France as the spearhead of the key sector of biodrugs. Three of the program's priority projects are headed by Genopole laboratories.

Discover
©Lionel Antoni - Plateforme d'irradiation expérimentale du LRGK - Plateforme génopolitaine mutualisée avec les acteurs de la communauté scientifique francilienne

The Experimental Irradiation Platform to serve the Île-de-France scientific community

Genopole is making available to the Île-de-France scientific community an Experimental Irradiation Platform equipped with a state of the art generator

Discover
Laina Freyer directrice scientifique, Felome

Felome Launches the Commercialization of Genetic Analyses for Companion Cats

Felome will begin the commercialization of a service offering genetic analyses for companion cats, to reveal their predispositions to over 50 diseases, identify their main physical traits, and their similarities with 14 types of breeds.

Discover
Lauréats de la promo 3 du programme Gene.iO - Genopole

Three Gene.iO whiz kids rewarded for their innovations

Three Gene.iO whiz kids, Alga Biologics, Fungu'it and Alt Biotech, rewarded for their innovations. Alga Biologics was among the 35 start-ups included in the French Blue Tech Index. Fungu'it and Alt Biotech, were selected to participate in 212 Founders, a start-up accompaniment and financing program by CDG Invest.

Discover
l'équipe iGEM 2023 Evry Paris-Saclay - Médaille d'or et p

A prize and gold for the 2023 Évry Paris-Saclay iGEM team

The international synthetic biology competition iGEM celebrated its 20th anniversary. From across the globe, the event drew more than 7,000 students in 400 teams from 66 countries. Genopole was there, among other actors in synthetic biology, to present the biocluster's advantages at its stand, and support the 17 students of the Évry Paris-Saclay team and their outstanding project, OptoGenEYEsis.

Discover
View all >
With the support from
Région île de France